The Girona-based company mjn-neuro is one of the start-ups benefiting from EIT Health’s Start-up Amplifier Instrument program, an initiative that helps start-ups gain access to new European markets. The 2.76 million euros grant will allow mjn-neuro to enter the European market with its mjn-SERAS device, the first product worldwide capable of warning in advance of a crisis of epilepsy.

Last year the company launched the product in Spain and they already have several agreements in the United Kingdom and the Netherlands. "After the initial launch in Spain, we want to continue working to get our product to everyone who needs it and improve their quality of life in Europe," says David Blánquez, CEO of mjn-neuro. "We are grateful for the support of EITHealth and the European Commission, which, through this program, will allow us to carry out a European clinical trial and establish contact and agreements with prestigious companies and hospitals in Europe to extend our device toother markets.”

The clinical study proposed in this project will not only measure the clinical aspects of the disease, but also the mental and social aspects of patients with refractory epilepsy, such as stress, depression, and quality of life, according to the definition of health of the WHO. 

mjn-neuro was founded in 2014, focusing on the design, manufacture and marketing of medical devices that improve people's quality of life. The company’s first product, mjn-SERAS, is already available in Spain; and they started with the development of DREAMER, focused on Alzheimer’s disease.